Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cardax Inc CDXI

Healthcare Biotechnology
Cardax, Inc. is a geroscience company focused on pharmaceutical and nutraceutical applications of astaxanthin. The Company markets ZanthoSyn, an astaxanthin dietary supplement for lifespan and health span (inflammatory health), including joint and muscle function, cognitive performance, and cardiovascular health. ZanthoSyn is available through its commercial Website. ZanthoSyn contains pure... see more

Current News (GREY:CDXI)

Cardax Refocuses on ZanthoSyn® Consumer Health Business

PR Newswire August 31, 2021

Cardax, Inc. Announces Reverse Stock Split of Common Stock

PR Newswire January 14, 2020

Cardax Reports Q3 2019 Results

PR Newswire November 14, 2019

Cardax Announces Interim Results from CHASE Clinical Trial

PR Newswire September 23, 2019

Cardax Reports Q2 2019 Results

PR Newswire August 14, 2019

Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering

PR Newswire August 14, 2019

Cardax Reports Q1 2019 Results

PR Newswire May 17, 2019

Cardax Reports 2018 Results

PR Newswire March 28, 2019

Cardax to Present at NobleCon XV

PR Newswire January 25, 2019
View More News ››

Opinion & Analysis (GREY:CDXI)

No current opinion is available.
View More Opinion ››

Bullboard Posts (GREY:CDXI)

Be the first to post on this bullboard.

Leading Edge Materials Corp.

Leading Edge Materials Corp.

Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects ...
View More »